A 55-year-old patient with a history of hypertension, diabetes, and a family history of coronary artery disease (CAD) presents with chest pain and shortness of breath. Which risk factor is likely to contribute significantly to the development of CAD in this patient?

A. Prescribing an antihypertensive medication treats the specific symptom of elevated blood pressure but does not address the patient's sedentary behavior. While pharmacological control is important, it does not provide the broad metabolic benefits associated with physical activity. Lifestyle changes often reduce the dose or necessity of such medications by improving vascular tone.

B. Recommending regular exercise and lifestyle modification targets multiple modifiable risk factors, including the patient's sedentary habits and hypertension. Aerobic exercise improves endothelial function, lowers systemic vascular resistance, and optimizes the lipid profile. This holistic approach is the most effective way to counteract the patient's nonmodifiable family history of coronary disease.

C. Advising routine blood glucose monitoring is a primary intervention for individuals with diagnosed diabetes or impaired glucose tolerance. Since this client is a non-diabetic, routine monitoring provides no direct benefit in reducing the progression of atherosclerosis. Energy should be focused on active risk reduction strategies rather than monitoring for a condition not present.

D. Initiating a smoking cessation program is the most critical intervention for active smokers to prevent acute coronary syndromes and chronic inflammation. However, the patient in the scenario is explicitly identified as a non-smoker. Providing resources for smoking cessation would be irrelevant to this specific patient's clinical needs and risk profile.

A. Salmeterol is a long-acting beta-agonist used strictly for the long-term maintenance and prophylaxis of bronchospasm in chronic asthma or COPD. It possesses a delayed onset of action and does not provide the immediate smooth muscle relaxation required during a life-threatening acute exacerbation. Using a LABA as a rescue medication is contraindicated because it cannot rapidly reverse the acute narrowing of the airways.

B. Montelukast is a leukotriene receptor antagonist that provides anti-inflammatory benefits by inhibiting the late-phase response to allergens and exercise. It is an oral maintenance medication that requires daily administration to achieve therapeutic levels in the systemic circulation. It has no direct bronchodilatory effect and is therefore entirely ineffective for the immediate management of an acute, symptomatic asthma attack in an emergency.

C. Ipratropium bromide is an anticholinergic agent that provides bronchodilation by blocking muscarinic receptors in the large airways. While it is frequently used in combination with beta-agonists for severe asthma exacerbations, it is not considered the stand-alone first-line therapy. Its onset of action is generally slower than that of beta-agonists, making it an adjunctive rather than a primary rescue medication in most clinical protocols.

D. Inhaled short-acting beta-agonists, such as albuterol, are the first-line treatment for acute asthma due to their rapid onset within minutes. These medications bind to beta-2 adrenergic receptors on pulmonary smooth muscle cells, increasing intracellular cyclic AMP and causing immediate muscle relaxation. This swift physiological reversal of bronchoconstriction is essential for increasing airflow and resolving the acute respiratory distress associated with an asthma flare.